Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PlyF307SQ-8C
- Development stage
- Discontinued
- Lead developer
- ContraFect
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Topical
01
Overview
PlyF307SQ-8C is an engineered, recombinant bacteriophage-derived endolysin (lysin) developed by ContraFect Corporation, specifically designed to target and kill *Acinetobacter baumannii*. It is a truncated and optimized variant of the native PlyF307 lysin, which was originally isolated from an *A. baumannii* phage. The molecule acts as a peptidoglycan hydrolase, rapidly degrading the bacterial cell wall upon contact, which leads to osmotic lysis and cell death. PlyF307SQ-8C has shown significant potency against multidrug-resistant (MDR) and carbapenem-resistant *A. baumannii* (CRAB) strains in preclinical studies, including the ability to disrupt biofilms. While it served as a key lead in ContraFect's Gram-negative program, the company's clinical focus shifted to CF-370 (a related engineered lysin) before ContraFect ceased operations and entered liquidation in late 2023.
- Other names
- PlyF307 variantPlyF-307 variantPlyF 307 varianttruncated PlyF307
02
Targets
PGN (Peptidoglycan)
Beyond the preview
Go deeper on PlyF307SQ-8C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PlyF307SQ-8C.